ALS blood expression profiling identifies new biomarkers, patient subgroups, and evidence for neutrophilia and hypoxia
Amyotrophic lateral sclerosis (ALS) is a debilitating disease with few treatment options. Progress towards new therapies requires validated disease biomarkers, but there is no consensus on which fluid-based me...
Source: Journal of Translational Medicine - Category: Research Authors: William R. Swindell, Colin P. S. Kruse, Edward O. List, Darlene E. Berryman and John J. Kopchick Tags: Research Source Type: research